Charles River Laboratories International (CRL) Gains Fresh Attention After Research Partnerships Raise Valuation Questions

Why Charles River Laboratories International drew fresh investor interest

Charles River Laboratories International (CRL) recently highlighted its Virtual Control Group program in a Good Laboratory Practice study for Ipsen, while also joining Labcorp and the U.S. FDA in a project on drug abuse potential assessment.

Those Ipsen and Labcorp collaborations arrive after a sharp run in Charles River Laboratories International’s shares, with a 30-day share price return of 23.85% and a 90-day gain of 53.52%, while the 1-year total shareholder return of 100.94% indicates strong longer term momentum.

Scan beyond Charles River Laboratories International and see how other contract research and biotech enablers are setting up in our hand picked list of 19 high quality undiscovered gems.

After a 1 year total return near 101% and a share price around US$359, the real puzzle on Charles River Laboratories International now is simple: is most of the upside already behind it or not yet priced in?

Most Popular Narrative: 14% Overvalued

On the most followed view, Charles River Laboratories International carries a fair value of about $315.53 against a last close of $359.41. This puts the focus firmly on whether the long term profit story can support that gap.

The main thing that has to go right is that higher value services such as bioanalysis and Manufacturing Solutions, supported by AI enabled workflow changes and internal primate sourcing, continue to shift the mix toward later stage and recurring testing while offsetting softer areas like RMS and government or academic demand.

Expansion of higher value services, including plans to grow bioanalysis revenue from about US$300m in 2025 to US$450m in 2030 and to shift Discovery and Safety Assessment mix toward a roughly 50% post IND contribution, is intended to deepen exposure to later stage and recurring testing, which would influence both revenue visibility and the margin profile across the cycle.

See why 4 investors see Charles River Laboratories International as 14% overvalued.

Result: Fair Value of $315.53 (OVERVALUED)

Still, the Charles River Laboratories International story can shift quickly if non animal testing methods gain traction faster than expected, or if refinancing roughly US$1.5b of senior notes bites harder into future earnings.

Find out about the key risks to this Charles River Laboratories International narrative.

Another View on Charles River Laboratories International’s Valuation

The first take on Charles River Laboratories International relies on an analyst fair value estimate of about $315.53 per share and characterizes the stock as roughly 14% overvalued relative to the recent $359.41 price. A second valuation approach points in a similar direction. Our DCF model estimates future cash flow value at $298.09, which also suggests a relatively high entry point. Investors may wish to consider which set of assumptions best fits their own hurdle rate for CRL.

Look into how the SWS DCF model arrives at its fair value.

Next Steps

If this mix of enthusiasm and caution around Charles River Laboratories International leaves you on the fence, move quickly and test the data against your own expectations, starting with the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Charles River Laboratories International?

Do not let the story stop with Charles River Laboratories International. Broaden your watchlist now so you are not late to the next opportunity.

• Target resilient candidates that aim to keep risk in check by scanning the 29 resilient stocks with low risk scores.
• Hunt for strong balance sheets and underlying fundamentals by working through the list of solid balance sheet and fundamentals (24 results).
• Spot potential value opportunities early by tracking the 36 high quality undervalued stocks.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com